Compare BridgeBio Pharma Inc (BBIO) vs Western Digital Corp (WDC) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

Western Digital (WDC) trades at $555.55, down 4.64% amid a sector-wide memory stock sell-off. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a net income margin of 55.07%, and robust cash flow from operations of $1.69B in 2025. Technical indicators are bearish, with price near the pivot point of $551. Analyst sentiment remains overwhelmingly positive with a 72% buy rating and a $619.07 consensus price target, suggesting significant upside potential.

The outlook is supported by AI-driven storage demand and margin expansion, but near-term volatility from memory pricing cycles and competitive pressures poses risks. The stock's high valuation multiples require sustained earnings growth to justify further appreciation.